A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration
Tekijät: Niiranen, Teemu J.; Schnabel, Renate B.; Schutte, Aletta E.; Biton, Yitschak; Boriani, Giuseppe; Buckley, Claire; Cameron, Alan C.; Damasceno, Albertino; Diederichsen, Soren Z.; Doehner, Wolfram; Guo, Yutao; Hobbs, F. D. Richard; Joung, Boyoung; Hankey, Graeme J.; Lip, Gregory Y. H.; Lobban, Trudie; Lochen, Maja-Lisa; Mairesse, Georges; Mbakwem, Amam; Noseworthy, Peter A.; Ntaios, George; Steinhubl, Steven; Stergiou, George; Svendsen, Jesper Hastrup; Tieleman, Robert G.; Wang, Jiguang; Poulter, Neil R.; Healey, Jeff S.; Freedman, Ben
Kustantaja: Ovid Technologies (Wolters Kluwer Health)
Kustannuspaikka: PHILADELPHIA
Julkaisuvuosi: 2025
Journal: Circulation
Tietokannassa oleva lehden nimi: Circulation
Lehden akronyymi: CIRCULATION
Vuosikerta: 151
Numero: 12
Aloitussivu: 863
Lopetussivu: 877
Sivujen määrä: 15
ISSN: 0009-7322
eISSN: 1524-4539
DOI: https://doi.org/10.1161/CIRCULATIONAHA.124.071047
Verkko-osoite: https://doi.org/10.1161/circulationaha.124.071047
Hypertension is the leading modifiable risk factor for atrial fibrillation (AF) and is estimated to be present in >70% of AF patients. This Frontiers Review was prepared by 29 expert members of the AF-SCREEN International Collaboration to summarize existing evidence and knowledge gaps on links between hypertension, AF, and their cardiovascular sequelae; simultaneous screening for hypertension and AF; and the prevention of AF through antihypertensive therapy. Hypertension and AF are inextricably connected. Both are easily diagnosed, often silent, and frequently treated inadequately. Together, they additively increase the risk of ischemic stroke, heart failure, and many types of dementia, resulting in greater all-cause mortality, considerable disease burden, and increased health care expenditures. Automated upper arm cuff blood pressure devices with implemented technology can be used to simultaneously detect both hypertension and AF. However, positive screening for AF with an oscillometric blood pressure monitor still requires ECG confirmation. The current evidence suggests that high-risk individuals aged >= 65 years or with treatment-resistant hypertension could benefit from AF screening. Since antihypertensive therapy effectively lowers AF risk, particularly in individuals with left ventricular dysfunction, hypertension should be the key target for AF prediction and prevention rather than merely a comorbidity of AF. Nevertheless, several important gaps in knowledge need to be filled over the next years, including the ideal method and selection of patients for simultaneous screening of hypertension and AF and the optimal antihypertensive drug class and blood pressure targets for AF prevention.
Julkaisussa olevat rahoitustiedot:
T.J.N. has received funding from the Finnish Research Council, the Sigrid Juselius Foundation, and the Finnish Foundation for Cardiovascular Research. Y.G. has received funding from the Beijing Natural Science Foundation of China (L232117) and the National Natural Science Foundation of China (82170309). R.B.S. has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program under the grant agreements 648131, 847770 (AFFECT-EU), and 101095480; the German Center for Cardiovascular Research (DZHK e.V.) (81Z1710103and 81Z0710114), the German Ministry of Research and Education (BMBF 01ZX1408A), and ERA-CoSysMed3 (031L0239), and the German Heart Foundation (Wolfgang Seefried Project Funding). A.E.S. is funded by a National Health and Medical Research Council of Australia investigator grant (APP2017504). A.C. is funded by Heart Research UK, the Stroke Association, the Chief Scientist Office Scotland, the Royal College of Physicians and Surgeons of Glasgow, Tenovus Scotland, the Mason Medical Research Trust, Pfizer, University of Glasgow, and NHS Greater Glasgow and Clyde. G.Y.H.L. is a National Institute for Health and Care Research (NIHR) Senior Investigator and coprincipal investigator of the AFFIRMO Project on Multimorbidity in AF, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement 899871. J.H.S. has received funding from Innovation Fund Denmark and the European Union Horizon 2020 program: AFFECT-EU. W.D. has received funding from the European Union's Horizon 2020 research and innovation program, the German Ministry of Education and Research, the German Center for Cardiovascular Research, Boehringer Ingelheim, and Vifor Pharma. B.F. is funded by Australian Government MRFF grants and an NSW Health Cardiovascular Capacity Building grant.
